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Abstract
Background: To compare the number of severe periprocedural bleeding complications from 
the total number of bleeding complications associated with diagnostic selective coronary an-
giography or percutaneous coronary intervention (PCI) when using different classifications 
(TIMI, GUSTO, PLATO, BARC) and to relate these classifications to real hemodynamic 
status of evaluated patients.
Methods: We analyzed data from 106 patients who underwent invasive procedure for ischemic 
heart disease (selective coronary angiography/PCI) and suffered from any type of bleeding 
complication.
Results: The number of bleeding according to impacts on hemodynamic status and conse-
quent treatment shows that 54.7% of all bleedings did not need any specific therapy. Bleeding 
leading to death, hemorrhagic shock, hemodynamic instability, administration of blood trans-
fusion, surgical procedure and local treatment occurred in 6.6%, 1.9%, 5.7%, 14.2%, 2.8%, 
and 14.2%, respectively. The results comparing bleeding classifications demonstrate that the 
rate of severe bleeding complications may increase up to 4 times when different classifications 
are used on the same group of patients (TIMI 9.4%, GUSTO 15.1%, PLATO 39.2% and 
BARC 35.9%). The power of association between severe bleeding determined by these classifi-
cations and real hemodynamic compromise using Kendall’s tau-c correlation is –0.4106 (95% 
CI –0.599 to –0.222), –0.5355 (95% CI –0.718 to –0.353), –0.5513 (95% CI –0.729 to –0.374) 
and –0.7552 (95% CI –0.897 to –0.612) for TIMI, GUSTO, PLATO and BARC, respectively.
Conclusions: The data show significant dependence of percentage of severe periprocedural 
bleeding complications on selected classification. The strongest association between severe 
bleeding and real hemodynamic status was found for BARC classification as this classification 
seems to be promising for future general use. (Cardiol J 2015; 22, 6: 665–674)
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Introduction
The treatment of patients with acute coronary 
syndrome (ACS), as well as those with stable form 
of ischemic heart disease (IHD) has developed 
rapidly in the last several decades. Invasive proce-
dures in cardiology, e.g. selective coronary angiog-
raphy (CAG) as a diagnostic method and percutane-
ous coronary intervention (PCI) as a therapeutic 
method have become part of a routine practice. 
With continuous improvement in technique of 
CAG and PCI, with new materials used and mainly 
with development of new types of more effective 
antiplatelet and anticoagulant drugs, the number 
of death rates according to ischemic events and 
periprocedural ischemic complications including 
ischemic stroke and heart failure has decreased to 
minimum and almost reached boundary for further 
reduction [1, 2]. On the other hand, older people 
and patients with wider range of comorbidities 
undergo invasive procedure as a therapeutic and 
very often it is the only diagnostic method for all 
forms of IHD [3].
All factors mentioned above are responsible for 
increased risk of bleeding complications in connec-
tion with invasive procedures [4]. As bleeding com-
plications are associated with worse short-term, as 
well as long-term prognosis for patients suffering 
from them, they become a noticeable medical and 
economical problem and so they are becoming more 
in a point of interest for all experts and clinicians 
[5–7]. The incidence of bleeding complication in 
clinical trials varies ranging from 2.0% to 17.6% 
differing according to population evaluated, cardiac 
catheterization technique, pharmacotherapy used 
and many others [4, 5, 8–10]. In most of recent 
large randomized clinical trials, the rate of bleed-
ing complications is used as a safety indicator for 
every new procedure in invasive cardiology and the 
rate of bleeding complications indicates safety of 
all newly introduced antiplatelet or anticoagulant 
drugs [11, 12].
Furthermore, in current era of evidence based 
medicine, it is then very important to compare 
acquired data from all those provided clinical tri-
als with each other. In association with bleeding 
complications, the comparability is now affected 
with wide number of different classifications that 
have been used for evaluation of those complica-
tions in last decades [13]. Each classification has 
been tailored according to study design meaning 
different outcomes are evaluated for in-hospital 
mortality of patients with ACS requiring rescue 
PCI than in classification for long term follow up 
evaluating wide range of bleeding events (including 
superficial bleeding, e.g. petechia).
This variability in bleeding classifications used 
across clinical trials led us to compare the most 
often used classifications. The aim was to find out 
how different outcomes may develop when vari-
ous classifications are used in one patient group. 
Then we correlate evaluation of each of those 
classifications with real seriousness of bleeding 
expressed by hemodynamic compromise and 
required treatment in context of finding that the 
clinical criteria are more important for sequential 
clinical outcomes.
Methods 
We analyzed periprocedural bleeding com-
plications in a group of patients who developed 
bleeding in association with CAG or PCI. Ethics 
Committees of participating institutions approved 
the study protocol. Patients were included in the 
study after signing an informed consent for par-
ticipation. No exclusion criteria were applied for 
study participation.
Basic demographic data, medical history, car-
diovascular risk factors, major comorbidities, clini-
cal status and laboratory findings were recorded. 
Medical history was obtained from patients’ medi-
cal documentation or personal interview. Clinical 
evaluation was performed during admission to the 
hospital and then relevant changes of clinical status 
were noted during hospitalization. Blood count was 
measured in all patients with a special emphasis 
on level of hemoglobin and hematocrit. The kidney 
function was monitored using creatinine clearance 
received by Cockroft-Gault formula. Also factors 
related directly to invasive procedure including 
number of affected vessels, administered anti-
platelet or anticoagulant drugs and type of arterial 
access (femoral or radial) were observed.
All bleeding complications that occurred 
relating to CAG or PCI were precisely described 
in every patient from multiple perspectives. In 
all patients, we observed the real hemodynamic 
compromise (according to the criteria listed 
below) and therapy required when any type of 
bleeding occurred. The hemodynamic status and 
its changes, the necessity of intensive care unit, 
administration of any blood transfusions as well 
as provided therapy were thoroughly monitored. 
Also, the localization of each bleeding was ob-
served by using various imaging techniques where 
needed and applicable (computed tomography 
[CT], ultrasound [US]).
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With all these collected data mentioned above 
we were able to process number of bleeding com-
plications according to different criteria. We evalu-
ated number of these complications according to 
i) hemodynamic compromise of the patients and 
subsequent need of treatment ii) localization of the 
bleeding. For evaluation hemodynamic compromise 
and subsequent treatment we established 7 con-
secutive groups according to severity of bleeding: 
1) bleeding with no need of treatment, 2) with 
local therapy needed, 3) with blood transfusion 
administration, 4) with surgical revision, 5) bleed-
ing leading to hemodynamic instability (defined as 
decrease in blood pressure affecting the function 
of any organ requiring intravenous solution or any 
supportive drug administration which do not meet 
criteria for hemorrhagic shock), 6) bleeding leading 
to hemorrhagic shock (defined as bleeding meet-
ing at least 3 following criteria: with systolic blood 
pressure < 90 mm Hg, tachycardia > 120/min, 
anuria, tachypnea > 30/min, quantitative or 
qualitative alteration of consciousness), 7) fatal 
bleeding. Then we applied on this group of patients 
4 different classifications of bleeding complications 
that are standardly used for evaluating data from 
large randomized cardiovascular clinical trials — 
Thrombolysis in Myocardial Infarction (TIMI), 
Global Use of Strategies to Open Occluded Arter-
ies (GUSTO), Platelet Inhibition and Patient Out-
comes (PLATO) and Bleeding Academic Research 
Consortium (BARC) [12, 14–16]. The TIMI and 
GUSTO classification were chosen as representa-
tives of the basic and simple classifications with 
opposite monitored values (laboratory vs. clinical 
data). Detailed criteria of each classification are 
displayed in Supplementary Table S1 and Supple-
mentary Table S2. The PLATO was selected as an 
example of independent classification with fusion 
of both laboratory and clinical data and the BARC 
classification as a representative of the newest 
and highly elaborated bleeding classification. Due 
to these classifications we observed percentage 
of severe complications, as for better comparabil-
ity were marked as severe in PLATO together 
life-threatening and other severe bleeding and in 
BARC classification together number of bleeding 
from group 3a–5b. Then we were able to compare 
the differences in rate of severe complications in 
each group.
Finally, we made a correlation between the 
seriousness of bleeding according to hemodynamic 
compromise with each bleeding classification sepa-
rately. Each of the 4 representative classifications 
provides an ordinal scale. The scales given by clas-
sifications TIMI, GUSTO and PLATO distinguish 
3 degrees of bleeding severity, while BARC pro-
vides a more complex scale. The hemodynamic 
status is also described by an ordinal scale which 
distinguishes 7 levels defined above. As the rela-
tions between each of the 4 classifications and 
patients’ real hemodynamic status were to be 
compared, the most suitable statistic to use was 
Kendal’s tau-c. Kendal’s tau-c coefficient ranges 
from –1 to 1 meaning strong negative and strong 
positive association, respectively. The values close 
to –1 signify the higher degree of particular clas-
sification the worse hemodynamic status, therefore 
the strongest correlation. The values close to 1, on 
the contrary, indicate increase in severity of bleed-
ing due to bleeding classification with conversely 
improving hemodynamic status. The values close 
to 0 can be interpreted as no association between 
bleeding severity and the hemodynamic compro-
mise [17]. The Kendal’s coefficients were obtained 
with the use of STATISTICA, version 10.
Results
The study population consists of 106 patients 
who developed bleeding complication in association 
with invasive procedure performed for any form 
of IHD from 5 cardio centers from Czech Republic 
(Prague, Pilsen, Olomouc, Zlin, Ostrava) between 
2006 and 2012. Only patients with all data required 
for analysis were included. There were enrolled 
patients with ACS (STEMI, NSTEMI, unstable 
angina pectoris), which represent 54%, as well as 
patients who underwent elective CAG for stable 
forms of IHD (46%). In 49% of patients, selective 
CAG without any intervention was performed, 51% 
patients underwent PCI; 89% of all interventions 
were performed via femoral artery, 11% via radial 
artery. More characteristics related to invasive 
procedure are displayed in Table 1. Mean age was 
69 ± 11 years, 64% patients were female. Other 
characteristics are summarized in Table 2.
The number of bleeding complications ac-
cording to localization shows that the most often 
bleeding occurred at access site (84.9%) while the 
ratio of femoral vs. radial access in this subgroup 
remains the same as in global study population 
(89% femoral artery and 11% radial artery). Other 
localizations were: intracerebral 0.9%, cardiac 
tamponade 1.9%, gastrointestinal bleeding 1.9%, 
retroperitoneal bleeding 4.7%, epistaxis 0.9%, 
hematuria 1.9% and in 2.8% of bleeding the exact 
localization was not found (Table 3). When count-
ing rate of bleeding according to hemodynamic 
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status and consequent treatment the bleeding with 
no need of specific therapy represents more than a 
half of all bleedings (54.7%), 14.2% patients needed 
local treatment and 2.8% had to undergo surgical 
procedure. Blood transfusion had to be administered 
in 14.2% patients. Severe complications as hemody-
namic instability and hemorrhagic shock that needed 
intensive treatment at coronary unit appeared in 
5.7%, resp. 1.9%. The most severe bleeding leading 
to death occurred in 6.6% (Table 4).
When TIMI classification, which relies mainly 
on laboratory criteria, was applied on our study 
population, the rate of severe bleeding complica-
tions was 9.4%. Using GUSTO classification that 
is based mainly on clinical data, the percentage of 
severe bleeding complication was counted 15.1%. 
The PLATO and BARC classification are more 
complex and take into account both clinical and 
laboratory data. In these cases, the incidence of 
Table 1. Procedure relate d characteristics.
ACS total 57 (54%)
STEMI 13 (12%)
NSTEMI 23 (22%)
Unstable angina pectoris 20 (19%)
Ventricular fibrillation 1 (1%)
Non-ACS 49 (46%)
Stable angina pectoris 32 (30%)
Valvular heart disease 9 (8%)
Heart failure 6 (6%)
Other 2 (2%)
PCI 52 (49%)
CAG (without any intervention) 54 (51%)
Femoral access 94 (89%)
Radial access 12 (11%)
Left main coronary artery lesion 6 (5.7%)
Number of affected vessels:
3-vessel disease 27 (25%)
2-vessel disease 23 (22%)
1-vessel disease 20 (19%)
Normal CAG/coronary atherosclerosis 34 (32%)
N/A 2 (2%)
Periprocedural medication:
ASA 13 (12%)
ADP antagonists 38 (36%)
Heparin/LMWH 56 (53%)
GP IIb/IIIa inhibitors 8 (8%)
Other 5 (5%)
ACS — acute coronary syndrome; STEMI — ST elevation myo-
cardial infarction; NSTEMI — non-ST elevation myocardial infarc-
tion; PCI — percutaneous coronary intervention; CAG — coronary 
angiography; ASA — acetylsalicylic acid; ADP — adenosine  
diphosphate; LMWH — low molecular weight heparin;  
GP IIb/IIIa — glycoprotein IIb/IIIa; N/A — not available
Table 2. Baseline characteristics.
Mean age ± SD 69.6 ± 11
Gender:
Male 38 (36%)
Female 68 (64%)
Body mass index [kg/m2]:
< 20 2 (1.9%)
20–25 23 (21.7%)
25–30 44 (41.5%)
30–35 19 (17.9%)
35–40 11 (10.4%)
> 40 4 (3.8%)
Smoking:
Smoker 22 (21%)
No smoker 59 (56%)
Ex smoker 25 (24%)
History of IHD 44 (42%)
Previous PCI 13 (12%)
Previous CABG 9 (8%)
Arterial hypertension 80 (75%)
Diabetes mellitus 32 (30%)
Treatment of diabetes mellitus:
Insulin therapy 6 (19%)
Oral anti-diabetic medication 9 (28%)
Diet 8 (25%)
No treatment 3 (9%)
N/A 6 (19%)
Dyslipidemia 55 (52%)
Peripheral artery disease 9 (8%)
Stroke 8 (8%)
Atrial fibrillation 18 (17%)
Chronic kidney disease 71 (67%)
Chronic kidney disease stage:
2 28 (39%)
3 32 (45%)
4 6 (8%)
5 5 (7%)
History of bleeding 7 (7%)
History of pulmonary embolism/DVT 10 (9%)
Known coagulopathy 0 (0%)
Malignity in history 6 (6%)
SD — standard deviation; IHD — ischemic heart disease;  
PCI — percutaneous coronary intervention; CABG — coronary  
artery bypass grafting; DVT — deep venous thrombosis; N/A — 
not available
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severe bleeding was counted 39.6% for PLATO 
classification and 35.9% for BARC classification 
(Fig. 1).
Then we counted the number of severe bleed-
ing complications according to each scale (TIMI, 
GUSTO, PLATO, and BARC) in all groups of 
patients presented with different hemodynamic 
changes separately. All classifications show bleed-
ing as major (100%) in the fatal bleeding category. 
At the second pole of the severity, meaning bleed-
ing with no need of treatment or local therapy, the 
classifications seem to be also quite consistent. 
Most of them are marked as minor. In a group 
where no treatment was necessary, there was 
a minor marked 100% with TIMI classification, 
100% with GUSTO, 87% with PLATO and 93% 
with BARC classification. In a group of patients 
who underwent local therapy, 100% bleeding were 
marked as minor with using TIMI classification, 
93% with GUSTO, 80% with PLATO and 73% 
with BARC classification. The results then vary 
depending on which classification was used in 
other categories. In the second severe bleeding 
condition with hemorrhagic shock, TIMI clas-
sification marks as severe only 50% while other 
3 classifications indicate bleeding as severe in all 
cases. The differences are even more striking in 
next 3 boxes. Patients who presented with hemo-
dynamic instability are marked as severe in 67% 
using BARC classifications, in 100% using PLATO 
and GUSTO and contrary in 83% are marked as 
minor when TIMI applied. Similar situation arises 
in a group of patients needed blood transfusion or 
surgical revision where TIMI and GUSTO show 
opposite results in a rate of major bleeding than 
PLATO and BARC classifications. Details are dis-
played in Figure 2.
Finally, we compared how hemodynamic com-
promise relates with each of these bleeding clas-
sifications, meaning the tightness of bounding 
between these 2 parameters. For that purpose the 
Kendall’s tau-c was used and its numerical value 
for TIMI classification is –0.4719 (95% CI –0.633 
to –0.311), for GUSTO –0.6952 (95% CI –0.827 
to –0,564), for PLATO –0.6520 (95% CI –0.776 
to –0.528) and for BARC –0.5991 (95% CI –0.701 
to –0.500) using their extended version. When it 
is applied to the merged version of bleeding clas-
sifications focusing explicitly to serious bleeding 
complications, the value for TIMI is –0.4106 (95% 
CI –0.599 to –0.222), for GUSTO –0.5355 (95% 
CI –0.718 to –0.353), for PLATO –0.5513 (95% 
CI –0.729 to –0.374) and for BARC –0.7552 (95% 
CI –0.897 to –0.612). The strongest association 
Figure 1. Number of severe bleeding complications 
using TIMI, GUSTO, PLATO and BARC classifications.
Table 3. Number of bleeding according  
to localization.
Localization of bleeding N (%)
Intracerebral 1 (0.9%)
Cardiac tamponade 2 (1.9%)
Gastrointestinal bleeding 2 (1.9%)
Retroperitoneal 5 (4.7%)
Epistaxis 1 (0.9%)
Hematuria 2 (1.9%)
Access site hematoma 90 (84.9%)
Unknown localization 3 (2.8%)
Table 4. Number of bleeding according to 
hemodynamic status and consequent treatment.
Type of bleeding N (%)
Fatal bleeding 7 (6.6%)
Bleeding with hemorrhagic shock 2 (1.9%)
Bleeding with hemodynamic instability 6 (5.7%)
Bleeding with transfusions needed 15 (14.2%)
Surgical revision 3 (2.8%)
Local therapy 15 (14.25)
With no need of treatment 58 (54.7%)
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with the hemodynamic compromise was found for 
merged version of BARC classification and also the 
95% confidence interval (CI) shows the smallest 
variability in BARC classification (in both cases 
comparing extended or merged version).
Discussion
Our results show significant differences in 
number of severe bleeding complications that may 
lead to huge heterogeneity in presentation of out-
comes when different classifications are used and 
that classifications do not always reflect the real 
hemodynamic compromise of the patient and so it 
could underestimate the real risk. The differences 
are emphasized mainly for those bleeding compli-
cations that are classified in the middle part of the 
scale (meaning not life-threatening or minimal).
When focused on localization (Table 3) it 
is obvious that the greatest number of bleeding 
complications appeared at access site (85%). The 
evaluation of influence on hemodynamic status 
in the same group of patients shows more equal 
stratification (Table 4). These findings suggest 
that even access site bleeding may result in very 
serious condition with fatal outcome. Even if 55% 
of patients did not need any specific treatment 
at the moment, the bleeding may prolong their 
hospitalization, which in turn may bring many 
other complications leading to increased morbidity 
and mortality [18]. Also, administration of blood 
transfusion, which occurred in 14.2% of patients, 
is associated with higher rate of morbidity and 
mortality and it is not recommended as routinely 
as before [19]. All these factors mentioned above 
contribute to worse short-term, as well as long-
term prognosis for all patients who demonstrate 
bleeding. Therefore bleeding, as an indicator of 
safety of all newly introduced procedures and 
drugs affecting hemostasis in cardiology, is very 
preciously observed and reported in all clinical 
trials using different bleeding classifications.
The first formal classification of bleeding com-
plications associated to treatment of patients with 
ACS was introduced in 1988 as a part of the TIMI 
trial [14]. The TIMI classification is based mainly 
on laboratory criteria. The second widespread 
classification was introduced in GUSTO trial in 
1993 [15]. This classification, compared to TIMI 
classification, relies mainly on clinical outcomes. 
These 2 classifications, more or less modified, 
have been used in many clinical trials [20, 21]. 
Their limitations seem to be in preferable use of 
pure laboratory or pure clinical criteria. This is the 
Figure 2. Comparison of bleeding according to hemodynamic status and rate of major bleeding of each bleeding 
classifications.
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reason why numbers of different classifications, 
combining advantages of both, have been devel-
oped since then [22–24]. Specific classification for 
evaluation of bleeding complications, containing 
combination of clinical and laboratory criteria, was 
then estimated for PLATO trial [12]. Supplemen-
tary Table S1 displays detailed definition of these 
classifications. It is obvious that in that wide range 
of classifications it is almost impossible to compare 
clinical outcomes across executed studies [25]. In 
response to this situation, the tendency of estab-
lishing one standardized classification has arisen 
[26]. After a few attempts earlier, finally in 2011, 
BARC, a group of independent experts summarized 
all known evidence and data from clinical trials and 
evaluated new standardized bleeding classification 
for cardiovascular clinical trials (Supplementary 
Table S2) [27]. This classification seems to be 
comprehensive enough and meets all criteria for 
comfortable general use but was not proven yet in 
a clinical practice [16].
From wide range of the bleeding classifica-
tions that are normally used in large randomized 
clinical trials we applied 4 of them in our group of 
patients. Using 4 different classifications (TIMI, 
GUSTO, PLATO and BARC) we observed per-
centage of severe bleeding complications, as for 
better comparability we merged categories of 
severe bleeding in PLATO and BARC classifica-
tion into one group. The results after application 
of these 4 different classifications scales on one 
group of patients show significant differences be-
tween incidences of severe periprocedural bleed-
ing complications depending on classification 
used. The rates of severe bleeding complication 
were significantly lower when the simplest clas-
sifications, TIMI and GUSTO, were applied (9.4% 
and 15.1%, respectively). Using more complex 
classification that is in our study represented by 
classification from PLATO trial, the rate of severe 
bleeding complications increases almost 4-times 
(39.6%). Similar percentage of severe complication 
which was reached with PLATO classification was 
also achieved with BARC classification (35.9%). 
Except for finding that outcomes may be strongly 
influenced with selected classification, these data 
may indicate that using simpler and limited classi-
fication (using pure laboratory or pure clinical data) 
could underestimate the number of severe bleeding 
complications. These data also support current rec-
ommendation for all clinicians and researchers to 
use one standardized bleeding classification. When 
comparing these classifications in their original 
extended version, BARC classification seems to be 
the most systematic, complex and thus the most 
suitable for that purpose.
A clinical trial comparing TIMI and GUSTO 
classification proved that bleeding complications 
assessed with clinical criteria (GUSTO) show to be 
more important than those assessed by laboratory 
criteria (TIMI) in terms of clinical outcomes (death/ 
/myocardial infarction) [13]. These findings led us 
to assume that the real hemodynamic compromise 
caused by bleeding may be an approximate indica-
tor of potential dangerousness of each bleeding 
episode. So we counted a number of severe bleed-
ing complications separately (using 4 classifications 
above) in each category of hemodynamic changes 
due to bleeding. With this analysis we found even 
bigger diversity in outcomes resulting from the 
types of classification was used. At two opposite 
poles, meaning the most serious clinical condi-
tions resulting in deaths on the first pole and the 
bleeding with no need of treatment or with a need 
of local therapy on the second pole, the results in 
number of major vs. minor bleeding show similar 
incidence in all used classification. Meanwhile, the 
differences are rising rapidly in the middle part of 
the notional scale. But even when very serious 
clinical conditions appeared with an intensive 
coronary unit treatment (hemorrhagic shock and 
hemodynamic instability caused by bleeding) the 
data resulting from using different classifications 
led to significantly different and sometimes almost 
opposite outcomes (Fig. 2).
Therefore, finally, we measured the power of 
association between the real clinical and hemody-
namic status and the severity of bleeding defined 
by each classification. The results show that in 
original extended version of all classifications the 
association is found to be strongest for GUSTO 
classification and the weakest for TIMI. The strong 
association in GUSTO classification is expected 
and can be explained using pure clinical data in this 
classification (the same as the weakest association 
in TIMI classification that does not reflect clinical 
statement at all). However, when the same meas-
urement of association is applied on the merged 
version of bleeding classifications (reflecting all 
severe bleedings in one group) the strongest corre-
lation with the real clinical condition is found when 
using BARC classification. The weakest association 
remains using TIMI classification.
Limitations of the study
There are several limitations that should 
be addressed. The major limitation is the small 
sample size with small number of patients with 
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hemodynamic instability, shock or fatal bleeding, 
but according to low rate of bleeding in general, the 
appearance of bleeding complications, particularly 
the most serious, is very low. In one of the most re-
cent clinical trial, ACCOAST trial, where only high 
risk patients with ACS were enrolled, composite of 
major and minor TIMI bleeding in a control group 
occurred in 1.2%, life-threatening bleeding oc-
curred in 0.51% and no fatal bleeding was observed 
[28]. If we anticipated the total number of patients 
who underwent CAG/PCI in our work according to 
data above, it would match almost 9,000 examined 
patients. As we evaluated both patients with ACS, 
as well as those with stable form of IHD, and as 
in most participating centers the radial access is 
preferred, the incidence of bleeding is assumed to 
be even lower.
Secondly, the study population included both 
patients undergoing elective invasive procedure 
and patients with ACS. According to this limita-
tion, we cannot estimate the incidence of bleeding 
and identify any risk factors of bleeding events. 
However, the purpose of the study was to prove 
the utility and correlation of different bleeding clas-
sifications in real clinical practice, not to identify 
risk factors for bleeding.
Conclusions
All these findings demonstrate how different 
classification may strongly affect outcomes from 
clinical trials and then subsequently strongly influ-
ence the recommendations for evidence based treat-
ment of patients with IHD. One unified classification 
that could be used generally in practice and across 
clinical trials in cardiology seems to be necessary. 
The classification must be constructed to capture all 
bleeding events that are important and meaningful as 
for patients as for clinical outcomes while remaining 
simple, broadly applicable and easy for use. Recently 
introduced BARC classification seems to meet all 
those criteria for applicability in routine clinical 
and research practice. In that case, all researchers, 
experts and clinicians should be aware of this new 
classification and report bleeding events according to 
this BARC definition so it could be proven in practice 
and the data can be comparable in the future.
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Supplementary Table S1. TIMI, GUSTO and PLATO bleeding classifications.
Major Minor Minimal
TIMI Fatal, intracranial or associated 
with a decrease in hemoglobin 
> 5 g/dL (or 15% in hematocrit)
Hemoglobin decreasing  
> 3 g/dL (or hematocrit  
decreasing at least 10%)
Any other bleeding
Severe Moderate Mild
GUSTO Intracerebral or if it resulted in 
substantial hemodynamic  
compromise requring treatment
Need for transfusion Other bleeding, not requiring 
transfusion or causing  
hemodynamic compromise
Fatal/life-threatening Major Minor
PLATO Fatal bleeding, intrapericardial 
bleeding with cardiac tampon-
ade, intracranial bleeding, severe 
hypotension, hypovolemic shock 
due to bleeding, decline in  
hemoglobin of 5.0 g/dL, need for 
transfusion more than 4 units
Clinical significant disability,  
drop of hemoglobin 3–5 g/dL, 
requiring 2–3 units red blood 
cell transfusion
Any bleeding event requiring 
medical intervention but not 
meeting the criteria for major 
bleeding
Æ
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Supplementary Table S2. BARC bleeding classification.
Type Description
0 No bleeding
1 Bleeding that is not actionable and does not cause the patient to seek unscheduled performance  
of studies, hospitalization, or treatment by a health care professional
2 Any overt, actionable sign of hemorrhage (e.g. more bleeding than would be expected for a clinical  
circumstance; including bleeding found by imaging alone) that does not fit the criteria for type 3, 4,  
or 5, but does met at least one of the following criteria: (1) requiring non-surgical, medical intervention 
by a health care professional, (2) leading to hospitalization or increased level of care, (3) prompting 
evaluation
3
3a Overt bleeding plus hemoglobin drop of 3 to 5*g/dL (provided hemoglobin drop is related to bleed)
Any transfusion with overt bleeding
3b Overt bleeding plus hemoglobin drop ≥ 5*g/dL (provided hemoglobin drop is related to bleed)
Cardiac tamponade
Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid)
Bleeding requiring intravenous vasoactive drugs
3c Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation;  
does include intraspinal)
Subcategories; confirmed by autopsy or imaging or lumbar puncture
Intra-ocular bleed compromising vision
4: CABG- 
-related  
bleeding
Perioperative intracranial bleeding within 48 h
Reoperation following closure of sternotomy for the purpose of controlling bleeding
Transfusion of ≥ 5 units of whole blood or packed red blood cells within a 48 h period**
Chest tube output ≥ 2 L within a 24 h period
If a CABG-related bleed is not adjudicated as at least a type 3 severity event, it will be classified  
as ‘not a bleeding event’
5: fatal  
bleeding
5a Probable fatal bleeding: no autopsy or imaging confirmation, but clinically suspicious
5b Definite fatal bleeding: overt bleeding or autopsy or imaging confirmation
Platelet transfusions should be recorded and reported, but are not included in these definitions until further information is obtained about 
the relationship to outcomes; *Corrected for transfusion (1 U packed red blood cells or 1 U whole blood = 1 g/dL hemoglobin); **Only allo-
geneic transfusions are considered transfusions for BARC type 4 bleeding. Cell saver products will not be counted; CABG — coronary artery 
bypass grafting
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